Adapting Oncology Clinical Research Practices and Therapeutic Development Strategies in the Global COVID-19 Era, Upcoming Webinar Hosted by Xtalks
In this free webinar, the featured speakers will discuss considerations for adapting clinical and research practice on cancer disease management during the COVID-19 pandemic. Attendees will learn about the scientific rationale for re-tasking oncology drugs for COVID-19 patient treatment and strategies for managing patients and moving beyond the pandemic.
TORONTO, June 24, 2020 /PRNewswire-PRWeb/ -- The live session takes place on Tuesday, July 14, 2020 at 10am EDT (3pm BST/UK).
Cancer treatments and research have been severely impacted by the COVID-19 pandemic, and many questions remain about how to balance the management of care with patient safety. To better understand the effect of the disruption, four medical oncology specialists will participate in a unique panel discussion. Join these panelists as they share their thoughts from multiple viewpoints across the globe in this educational discussion that spans industry, academia and patient care perspectives.
First, the panelists will discuss scientific and clinical considerations, sharing how the pandemic has affected their ability to treat patients in clinical practices and trials as well as the impact on clinical trial participation. Following a series of guided questions, they will provide their candid thoughts on the role of virtual tools and technologies in decentralized clinical trials (DCTs) in the post-pandemic era in order to minimize exposure and de-risk trials. They will also discuss the potential of maintaining ongoing collaborations among drug development stakeholders, both within oncology and other therapeutic areas, in the effort to ensure continuity in clinical trials.
The second half of the webinar will focus on the emerging knowledge of SARS-CoV-2 biology. Increasing evidence points to the key role played by inflammation, immune dysfunction and thrombophilia in the pathophysiology of COVID-19. Multiple clinical trials are underway to test repurposed cancer drugs for COVID-19. The panelists will discuss which ones may be most promising and the most efficient ways to advance development.
Join Kamal Veer Saini, MD, Senior Medical Director, Oncology, Covance Clinical Development Services, Giuseppe Curigliano, MD, PhD, Associate Professor of Medical Oncology at University of Milano, Chris Twelves, MD, FRCP, Professor of Clinical Cancer Pharmacology and Oncology, Director of the NIHR Leeds Clinical Research Facility, Javier de Castro Carpeño, MD, Head of the Medical Oncology Section of the La Paz University Hospital in Madrid and Begoña de las Heras Garcia, MD, Senior Medical Director, Oncology, Covance Clinical Development Services for an informative presentation.
This webinar is part of a scientific series Covance is offering focused on trends, challenges and opportunities associated with current and future applications in Oncology. Learn more and register for upcoming webinars on topics such as adoptive cell therapies, biomarker technologies for the detection of cancer driver mutations, novel targeted therapies and more.
For more information or to register for this event, visit Adapting Oncology Clinical Research Practices and Therapeutic Development Strategies in the Global COVID-19 Era.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
SOURCE Xtalks
Share this article